DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 7.61

Change

-0.02 (-0.26)%

Market Cap

USD 0.17B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.50 (+0.48%)

USD 18.39B
IVV:AU iShares Core S&P 500 AUD

-0.46 (-0.75%)

USD 11.33B
VGS:AU Vanguard MSCI International Sh..

-0.68 (-0.49%)

USD 10.39B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.40 (-0.69%)

USD 7.35B
IOZ:AU Ishares Core S&P/Asx 200

+0.18 (+0.53%)

USD 6.40B
VTS:AU Vanguard US Total Market Share..

-3.68 (-0.81%)

USD 5.71B
STW:AU SPDR® S&P/ASX 200 Fund

+0.26 (+0.34%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

-0.39 (-0.79%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

-0.19 (-0.44%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.72 (+0.51%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.18% 16% F 46% F
Dividend Return 0.35% 10% F 5% F
Total Return -2.83% 14% F 45% F
Trailing 12 Months  
Capital Gain -12.83% 6% D- 42% F
Dividend Return 2.87% 40% F 31% F
Total Return -9.96% 5% F 43% F
Trailing 5 Years  
Capital Gain 17.62% 34% F 59% D-
Dividend Return 11.31% 25% F 21% F
Total Return 28.93% 29% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 5.46% 61% D- 56% F
Dividend Return 7.38% 60% D- 56% F
Total Return 1.92% 55% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 8.41% 62% D 91% A-
Risk Adjusted Return 87.72% 78% C+ 93% A
Market Capitalization 0.17B 32% F 64% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.